Search results for "DASE"

showing 10 items of 1891 documents

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, inten…

AdultBlood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismType 2 diabetesIncretinsRisk AssessmentDiabetes mellitusInternal medicinemedicineElectronic Health RecordsHumansHypoglycemic AgentsMedical prescriptionSodium-Glucose Transporter 2 InhibitorsOriginal InvestigationAgedQuality Indicators Health CareRetrospective StudiesAngiologyCardiovascular risk Humans Hypoglycemic Agents Incretins Italy Male Middle Aged Retrospective Studies Risk Assessment Sodium-Glucose Transporter 2 Inhibitors Time Factors Treatment Outcome Quality Indicators Health Care Quality of care Type 2 diabetes Adult Aged Aged 80 and over Biomarkers Blood Glucose Cardiovascular Diseases Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Heart Disease Risk Factors Female Electronic Health RecordsAged 80 and overDipeptidyl-Peptidase IV Inhibitorsbusiness.industryMedical recordQuality of careType 2 diabetesRetrospective cohort studyMiddle AgedCardiovascular riskmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHeart Disease Risk Factorslcsh:RC666-701AlbuminuriaFemaleObservational studymedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation.

2006

Three commercial systems for whole blood separation were compared to obtain the buffy coat composed of platelet-rich plasma (BC-PRP) and leucocytes . These samples of the buffy coat were used to make a platelet gel (PG), which was used to measure platelet growth factor (PGF) release, to perform a white blood cell (WBC) count and to measure myeloperoxidase (MPO) release from WBCs. Aliquots of whole blood obtained from ten volunteers were distributed either to a blood cell separator (The Electa Cell-Separator (TM), E-CS) or to a tabletop centrifuge (Gravitational Platelet Sequestration System (TM), GPS) to prepare the BC-PRP. The third system combines the BC-PRP production by E-CS with a micr…

AdultBlood PlateletsBuffy coatFibrin Tissue AdhesiveBlood cellTransforming Growth Factor beta1Blood Transfusion AutologousLeukocyte CountThrombinTransforming Growth Factor betaWhite blood cellmedicineLeukocytesHumansPlateletPlatelet activationWhole bloodPeroxidasePlatelet-Derived Growth FactorWound HealingChromatographybiologyChemistryHematologyPlatelet Activationmedicine.anatomical_structureBiochemistryMyeloperoxidasebiology.proteinBlood Component RemovalGelsmedicine.drugTransfusion medicine (Oxford, England)
researchProduct

Involvement of hydrogen and lipid peroxides in acute tobacco smoking-induced platelet hyperactivity

1995

Previous studies have established that cigarette smoking results in acute platelet hyperaggregability. We investigated whether changes in plasma oxidative properties could occur after smoking and whether such changes could be responsible for this enhanced platelet activity. In the present work, we report that platelets from nonsmokers become hyperactive after incubation with plasma prepared from blood of smokers obtained 10 min after smoking. This effect was not observed with presmoking plasma and could be inhibited in vitro by adding either catalase or reduced glutathione plus peroxidase to plasma or 2,6-di-tert-butyl-p-cresol (BHT) to platelets before incubation. Comparison of pre- and p…

AdultBlood PlateletsMaleLipid Peroxidesmedicine.medical_specialtyPlatelet AggregationPhysiologymedicine.medical_treatmentFatty Acids NonesterifiedAntioxidantschemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumansPlateletPlatelet activationIncubationchemistry.chemical_classificationbiologyVitamin ESmokingThrombinFatty acidHydrogen PeroxideGlutathioneButylated HydroxytolueneMiddle AgedBlood Physiological PhenomenaAdenosine DiphosphateEndocrinologychemistryBiochemistryCatalasebiology.proteinCardiology and Cardiovascular MedicinePeroxidaseAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Results of an Open Clinical Trial of Brofaromine (CGP 11 305 A), a Competitive, Selective, and Short-Acting Inhibitor of MAO-A in Major Endogenous De…

1987

In an open clinical trial the authors treated 18 hospitalized patients suffering from endogenous depression with brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of type A monoamine oxidase (MAO). Four patients were defined as good responders, as they had a final HAMD score of between 0 and 7 points. Four patients were judged as improved, with final HAMD scores of between 8 and 15 points, while the remaining eight patients failed to respond (final HAMD score greater than or equal to 16 points). The major observations were a beneficial influence on drive in most patients, while paranoid symptoms worsened markedly, rendering the substance contraindicated in psych…

AdultBlood PlateletsMaleSerotoninMonoamine Oxidase Inhibitorsmedicine.medical_treatmentSleep REMTyraminePsychotic depressionPharmacologyPersonality AssessmentDexamethasonechemistry.chemical_compoundPiperidinesBrofaromineHamdmedicineHumansPharmacology (medical)Monoamine OxidaseDepression (differential diagnoses)AgedDepressive DisorderChemotherapybiologyElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthchemistryEndogenous depressionbiology.proteinFemaleMonoamine oxidase APsychologyPharmacopsychiatry
researchProduct

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.

2005

Summary Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

AdultCD4-Positive T-LymphocytesMaleImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsMatrix metalloproteinasemedicine.disease_causeMMP-7; Fas ligand; CD4T cells; HIV infectionFas ligandPlasma viral loadGeneticsHumansMedicineMolecular BiologyGenetics (clinical)Polymorphism Geneticbusiness.industryMetalloendopeptidasesGeneral MedicineMiddle AgedViral LoadAntiretroviral therapySoluble fas ligandCD4 Lymphocyte CountAnti-Retroviral AgentsApoptosisMatrix Metalloproteinase 7ImmunologyHIV-1business
researchProduct

Inhibition of dextromethorphan metabolism by moclobemide.

1998

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan in addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automat…

AdultCYP2D6animal structuresMonoamine Oxidase InhibitorsAdolescentMoclobemidePharmacologyDextromethorphanchemistry.chemical_compoundPharmacokineticsOral administrationDextrorphanMoclobemideMedicineHumansDrug InteractionsBiotransformationPharmacologybusiness.industryDextromethorphanDrug interactionAntidepressive AgentsDebrisoquinechemistryArea Under CurveBenzamidesbusinessmedicine.drugPsychopharmacology
researchProduct

Impairment of antioxidant enzymes, lipid peroxidation and 8-oxo-2'-deoxyguanosine in advanced epithelial ovarian carcinoma of a Spanish community.

2006

In the present study, we describe the changes of antioxidant enzyme activities and other oxidative stress-related parameters in a mediterranean cohort of women affected with epithelial ovarian carcinoma (EOC). For that purpose, the most representative enzymatic activities, such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) and the oxidized/reduced glutathione (GSSG/GSH) ratio have been analyzed in tumor tissue biopsies and compared with the normal tissue of the same patient. As oxidation products, the levels of malondialdehyde (MDA) as an indication of lipid peroxidation, and the DNA damaged base 8-oxo-2'-deoxyguanosine (8-oxo-dG) have been also measured. Ad…

AdultCancer Research8-Oxo-2'-deoxyguanosinemedicine.disease_causeAndrologyLipid peroxidationSuperoxide dismutasechemistry.chemical_compoundmedicineHumansNeoplasms Glandular and EpithelialAgedNeoplasm Stagingchemistry.chemical_classificationAged 80 and overOvarian NeoplasmsGlutathione PeroxidasebiologySuperoxide DismutaseGlutathione peroxidase8-Hydroxy-2'-deoxyguanosineDeoxyguanosineGlutathioneMiddle AgedMalondialdehydeCatalaseGlutathioneOncologyBiochemistrychemistry8-Hydroxy-2'-Deoxyguanosinebiology.proteinFemaleLipid PeroxidationOxidative stressDNA DamageCancer letters
researchProduct

PAI-1 Levels are Related to Insulin Resistance and Carotid Atherosclerosis in Subjects with Familial Combined Hyperlipidemia

2017

Familial combined hyperlipidemia (FCH) is a primary atherogenic dyslipidemia with insulin resistance and increased cardiovascular risk. Plasminogen activator inhibitor type 1 (PAI-1) and myeloperoxidase (MPO) activity are associated with proinflammatory and atherothrombotic risk. Our aim was to study the role played by PAI-1 and MPO activity in the carotid atherosclerosis prevalence in FCH subjects. 36 FCH unrelated subjects (17 women) were matched by age and body weight with 36 healthy normolipidemic subjects (19 female). Blood lipids, glucose, insulin, insulin resistance (homeostasis model assessment (HOMA)), MPO, and PAI-1 were determined in both groups. Carotid intima media thickness (…

AdultCarotid Artery DiseasesMale0301 basic medicinemedicine.medical_specialtyWaistmedicine.medical_treatmentHyperlipidemia Familial CombinedBlood lipids030204 cardiovascular system & hematologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicinePlasminogen Activator Inhibitor 1medicineHumansPeroxidasebiologybusiness.industryInsulinGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyEndocrinologyIntima-media thicknessCase-Control StudiesMyeloperoxidasebiology.proteinFemaleInsulin ResistanceMetabolic syndromebusinessBody mass indexJournal of Investigative Medicine
researchProduct

Involvement of caspase-3 and GD3 ganglioside in ceramide-induced apoptosis in Farber disease.

2000

Farber's disease (FD) is a rare genetic disorder caused by ceramidase deficiency, which results in ceramide accumulation in lung, liver, colon, skeletal muscle, cartilage, and bone. Although this disease has been symptomatically characterized, little is known about its molecular pathogenetic process. Because recent studies reported that ceramide accumulation induces GD3 ganglioside formation and apoptosis, we investigated, in tissue obtained via colonoscopy from seriously involved patients, the possible involvement of ceramide in FD colonocyte destruction. Histochemical and TUNEL analyses of paraffin-embedded sections revealed that 45 ± 4.3% of FD colonocytes showed morphological signs of …

AdultCeramidePathologymedicine.medical_specialtyHistologyColonCaspase 3ApoptosisCeramideschemistry.chemical_compoundGangliosidesmedicineGD3 gangliosideHumansIntestinal MucosaCaspaseFarber diseaseFarber diseaseTUNEL assaybiologyCaspase 3ApoptosiCell Biologymedicine.diseaseCeramidaseCaspaseK18EpitheliumActive caspase-3Lysosomal Storage Diseasesmedicine.anatomical_structurechemistryApoptosisCaspasesCancer researchbiology.proteinAnatomyActive caspase-3; Apoptosis; Caspases; Farber disease; GD3 ganglioside; K18; Anatomy; Cell BiologyThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
researchProduct

[Fabry disease in Italy: first epidemiologic and collaborative study].

2005

The authors sought to define the prevalence of Fabry disease and to establish the incidence and its natural history in Italy. The aim of this study was to point out the first clinical signs and symptoms to perform an early diagnosis and hence to start a specific therapeutic treatment. Fabry disease is an inborn error of metabolism caused by the deficiency of the lysosomal enzyme alpha-galactosidase A. Fabry disease is a severe X-linked disorder presenting with a higher morbidity between the third and the fourth decade of life. Fabry disease may be confused with other diseases or completely misdiagnosed: its frequency is estimated worldwide to be 1:117000. In Italy, 65 patients have been ide…

AdultDiagnosis DifferentialMaleAdolescentItalyalpha-GalactosidaseFabry DiseaseHumansFemaleAlgorithms
researchProduct